NCT02002767View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 16, 2013

Primary Completion Date

June 9, 2014

Study Completion Date

June 9, 2014

Conditions
Hepatitis C Virus
Interventions
DRUG

Velpatasvir

Velpatasvir 100 mg (2 x 50 mg tablets) administered orally

Trial Locations (5)

32809

Orlando

33014

Miami

55114

Saint Paul

78215

San Antonio

08011

Christchurch

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY